Loading…
← CockpitCompetitor Analysis › 4743.TWO Oneness Biotech Co., Ltd.Open in the cockpit ↗

Oneness Biotech Co., Ltd.4743.TWOCompetitor analysis, valuation and peers

Taiwan · TWD·Health Care›Pharmaceuticals: Major
Momentum neutral 57
Mkt cap
$580M
US dollars, full cap
Free float
67%
of shares outstanding
$/day
$2.55M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-18.4 pp
WACC 5.6%
Hurdle
n/a
no reverse DCF
Next earnings
93 days
19 Feb 2027
Close · TWDNT$43.80
1D-5.3%
1W-5.3%
1M-11.5%
3M-5.8%
6M-12.9%
YTD-21.2%
1Y-33.2%
ATR %5.1%
52w lowhigh42.9% off high

What Oneness Biotech does

No business profile yet.

Oneness Biotech at a glance

Size Oneness Biotech (4743.TWO) is a Taiwan Health Care company (Pharmaceuticals: Major) with a market value of $580M, the 389th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$43.80 on 18 Nov 2026.

Performance Over six months the shares fell 12.9%, against -24.7% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 5th highest of 21 in its peer set.

Growth Revenue grew 18.7% over the last twelve months (peer median -1.7%); the operating margin is -589.3% (peer median 5.6%).

Valuation It trades at 101.5× enterprise value to sales against a peer median of 3.1× (most expensive of 17).

Capital Return on invested capital runs 18.4 points below its cost of capital (5.6% WACC).

Next results Next results expected around 19 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 20264743.TWO 87Peer median 76
Six months, rebased to 100: Oneness Biotech against the median of its 20 peers (local-currency closes).

Oneness Biotech financials

Reported figures in TWD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueNT$140MNT$125MNT$117MNT$86.8MNT$1.07B
Revenue growth—+7%+35%-92%—
Gross profit-NT$242M-NT$261M-NT$362M-NT$382MNT$552M
EBITDA-NT$503M-NT$469M-NT$632M-NT$648MNT$250M
Net income-NT$216M-NT$1.04B-NT$1.17B-NT$1.31BNT$360M
Free cash flow-NT$233M-NT$471M-NT$392M-NT$485M-NT$937M
Capital expenditureNT$16.3MNT$26.5MNT$53.3MNT$90.9MNT$89.2M
Total debtNT$338MNT$371MNT$406MNT$432MNT$263M

Quarterly statements and history in the cockpit →

Oneness Biotech competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-30%-20%-10%-20%0%215722563613603439CGEMALMS300147ENTXIMMX688356600568600976301096002393300233DBV003850ZVRA45594743.TWO6-month return →1-month return →
Up and to the right = strong over both horizons. Oneness Biotech is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%0×50×100×215722563613603439ALMS300147688356301096ACRSZVRA45594743.TWORevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Oneness Biotech is the large dot.

Oneness Biotech competitors and peer comparison

How Oneness Biotech compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Oneness Biotech against its 20 peers (data as of 18 Nov 2026)
Measure4743.TWOPeer medianRank in peer set
1-month return-11.5%-11.1%10th lowest of 21
6-month return-12.9%-24.7%5th highest of 21
Distance from 52-week high-42.9%-44.0%10th highest of 21
Revenue growth (TTM)+18.7%-1.7%4th highest of 18
Operating margin-589.3%5.6%3rd lowest of 17
EV / Sales101.5×3.1×most expensive of 17
ROIC minus cost of capital-18.4 pp-2.7 pp3rd lowest of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Oneness Biotech 4743.TWOTaiwan$580M-13%+19%-589%101.5×n/an/a
Lepu Biopharma 2157.HKHong Kong$580M-43%+47%7%4.5×n/an/a
Abbisko Cayman 2256.HKHong Kong$578M-39%-83%-520%20.1×n/an/a
Beijing Tong Ren Tang Chinese Medicine 3613.HKHong Kong$577M-26%-21%32%1.9×-15.4%+2.8%
GuiZhou SanLi Pharmaceutical 603439.SSChina$583M-20%-6%5%2.6×20.9%+21.9%
Cullinan Therapeutics CGEMUnited States$585M-37%n/an/an/an/an/a
Alumis ALMSUnited States$569M-80%-67%-5,375%23.9×n/an/a
Xiangxue Pharmaceutical 300147.SZChina$591M-41%+3%-39%3.7×50.4%-12.3%
Entera Bio ENTXUnited States$568M+163%-100%n/an/an/an/a
Immix Biopharma IMMXUnited States$596M-20%n/an/an/an/an/a
Jenkem Technology 688356.SSChina$563M-30%+52%11%8.7×36.4%+11.2%
Zhong Zhu Healthcare 600568.SSChina$562M-22%-6%-34%6.2×n/an/a
JIANMIN PHARMACEUTICAL 600976.SSChina$598M-14%-2%8%0.9×-6.2%+6.5%
Hangzhou Bio-Sincerity Pharma-Tech 301096.SZChina$602M-38%+5%-30%7.5×n/an/a
Tianjin Lisheng Pharmaceutical 002393.SZChina$557M-24%-3%7%1.2×-5.8%+4.1%
Shandong Jincheng Pharmaceutical 300233.SZChina$604M-31%+2%4%1.2×-0.6%-1.6%
DBV Technologies DBV.PAFrance$604M-46%n/an/an/an/an/a
Aclaris Therapeutics ACRSUnited States$555M-23%-59%-1,412%69.1×n/an/a
Boryung 003850.KSSouth Korea$554M-13%+6%6%0.9×-3.1%+12.6%
Zevra Therapeutics ZVRAUnited States$552M-9%+75%31%2.4×-4.9%+51.6%
Zeria Pharmaceutical 4559.TJapan$552M-12%+12%15%1.0×-12.3%+11.1%

Questions

Which companies are Oneness Biotech's closest peers?
The cockpit's peer set: Lepu Biopharma (2157.HK), Abbisko Cayman (2256.HK), Beijing Tong Ren Tang Chinese Medicine (3613.HK), GuiZhou SanLi Pharmaceutical (603439.SS), Cullinan Therapeutics (CGEM), Alumis (ALMS), Xiangxue Pharmaceutical (300147.SZ), Entera Bio (ENTX).
Is Oneness Biotech expensive compared with its peers?
On ev / sales it trades at 101.5× against a peer median of 3.1×, most expensive of 17 in its peer set.
How has Oneness Biotech stock performed?
Over six months to 18 Nov 2026 the shares returned -12.9% against -24.7% for the median peer; over one year -33.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.